ArticleMolecular cancer2017

PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.

Ymera Pignochino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.